SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 15 04 2022
accepted: 08 08 2022
entrez: 29 8 2022
pubmed: 30 8 2022
medline: 1 9 2022
Statut: epublish

Résumé

The COVID-19 pandemic has been fueled by SARS-CoV-2 novel variants of concern (VOC) that have increased transmissibility, receptor binding affinity, and other properties that enhance disease. The goal of this study is to characterize unique pathogenesis of the Delta VOC strain in the K18-hACE2-mouse challenge model. Challenge studies suggested that the lethal dose of Delta was higher than Alpha or Beta strains. To characterize the differences in the Delta strain's pathogenesis, a time-course experiment was performed to evaluate the overall host response to Alpha or Delta variant challenge. qRT-PCR analysis of Alpha- or Delta-challenged mice revealed no significant difference between viral RNA burden in the lung, nasal wash or brain. However, histopathological analysis revealed high lung tissue inflammation and cell infiltration following Delta- but not Alpha-challenge at day 6. Additionally, pro-inflammatory cytokines were highest at day 6 in Delta-challenged mice suggesting enhanced pneumonia. Total RNA-sequencing analysis of lungs comparing challenged to no challenge mice revealed that Alpha-challenged mice have more total genes differentially activated. Conversely, Delta-challenged mice have a higher magnitude of differential gene expression. Delta-challenged mice have increased interferon-dependent gene expression and IFN-γ production compared to Alpha. Analysis of TCR clonotypes suggested that Delta challenged mice have increased T-cell infiltration compared to Alpha challenged. Our data suggest that Delta has evolved to engage interferon responses in a manner that may enhance pathogenesis. The in vivo and in silico observations of this study underscore the need to conduct experiments with VOC strains to best model COVID-19 when evaluating therapeutics and vaccines.

Identifiants

pubmed: 36037222
doi: 10.1371/journal.pone.0273430
pii: PONE-D-22-11201
pmc: PMC9423646
doi:

Substances chimiques

Antiviral Agents 0
K-18 conjugate 0
gamma-Globulins 0
Interferons 9008-11-1
Melphalan Q41OR9510P

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0273430

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM103434
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121322
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Commun. 2021 Oct 28;12(1):6220
pubmed: 34711813
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Virol. 2007 Jan;81(2):813-21
pubmed: 17079315
NPJ Vaccines. 2022 Mar 14;7(1):36
pubmed: 35288576
PLoS Pathog. 2021 Jan 19;17(1):e1009195
pubmed: 33465158
Nat Commun. 2021 Nov 12;12(1):6559
pubmed: 34772941
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Elife. 2021 Sep 27;10:
pubmed: 34569939
Viruses. 2021 Jan 19;13(1):
pubmed: 33477869
Cell. 2021 Jun 24;184(13):3426-3437.e8
pubmed: 33991487
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Lancet Infect Dis. 2021 Nov;21(11):1518-1528
pubmed: 34171232
Nature. 2022 Feb;602(7896):294-299
pubmed: 34818667
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
PLoS One. 2021 Oct 11;16(10):e0258513
pubmed: 34634066
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Am J Trop Med Hyg. 2020 Sep;103(3):1215-1219
pubmed: 32723427
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Front Public Health. 2021 Nov 30;9:775224
pubmed: 34917580
Cell Rep. 2022 Feb 15;38(7):110387
pubmed: 35134331
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Cell Host Microbe. 2020 Jun 10;27(6):863-869
pubmed: 32464098
Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):
pubmed: 34021074
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
mBio. 2022 Jun 28;13(3):e0068322
pubmed: 35420469
Clin Infect Dis. 2022 Aug 24;75(1):e1120-e1127
pubmed: 34487522
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7
pubmed: 34826623
Nat Med. 2021 Jul;27(7):1131-1133
pubmed: 34045737
Nat Commun. 2020 Nov 30;11(1):6122
pubmed: 33257679
PLoS Biol. 2021 Jul 12;19(7):e3001333
pubmed: 34252080
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Cell Mol Immunol. 2021 Nov;18(11):2557-2559
pubmed: 34635807
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Cell Rep. 2021 Sep 7;36(10):109679
pubmed: 34464610
J Autoimmun. 2021 Nov;124:102715
pubmed: 34399188
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Front Immunol. 2018 Sep 11;9:2061
pubmed: 30254639
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
EBioMedicine. 2021 Nov;73:103643
pubmed: 34689086
Angiogenesis. 2022 May;25(2):225-240
pubmed: 34714440
Viruses. 2021 Sep 05;13(9):
pubmed: 34578354
Elife. 2021 Nov 25;10:
pubmed: 34821555
J Virol. 2022 Mar 23;96(6):e0218421
pubmed: 35080423
Viruses. 2021 Dec 24;14(1):
pubmed: 35062231
J Virol. 2022 Jan 12;96(1):e0096421
pubmed: 34668775
Nature. 2022 Feb;602(7896):300-306
pubmed: 34823256
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32750141
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Viruses. 2022 May 11;14(5):
pubmed: 35632761
Lancet Reg Health Eur. 2021 Sep;8:100171
pubmed: 34278372
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Viruses. 2021 Mar 01;13(3):
pubmed: 33804556
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99
pubmed: 33476315

Auteurs

Katherine S Lee (KS)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Ting Y Wong (TY)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Brynnan P Russ (BP)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Alexander M Horspool (AM)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Olivia A Miller (OA)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Nathaniel A Rader (NA)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Jerome P Givi (JP)

Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University, Morgantown, WV, United States of America.

Michael T Winters (MT)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.

Zeriel Y A Wong (ZYA)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Holly A Cyphert (HA)

Department of Biological Sciences, Marshall University, Huntington, WV, United States of America.

James Denvir (J)

Department of Biomedical Sciences, Marshall University, Huntington, WV, United States of America.

Peter Stoilov (P)

Department of Biochemistry, School of Medicine, West Virginia University Morgantown, Morgantown, WV, United States of America.

Mariette Barbier (M)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Nadia R Roan (NR)

Department or Urology, University of California, San Francisco, San Francisco, CA, United States of America.
Gladstone Institute of Virology, San Francisco, CA, United States of America.

Md Shahrier Amin (MS)

Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University, Morgantown, WV, United States of America.

Ivan Martinez (I)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
West Virginia University Cancer Institute, School of Medicine, Morgantown, WV, United States of America.

Justin R Bevere (JR)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

F Heath Damron (FH)

Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, United States of America.
Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, WV, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH